You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Drug Formulary
About the Drug Formulary Email Drug Formulary Team

SUNItinib

( soo-NIT-in-ib )
Funding:
Exceptional Access Program
  • SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
  • SUNItinib - Metastatic renal cell carcinoma, with specific criteria
  • SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
... Show more tags
Other Name(s): Sutent®
Appearance: capsule In various strengths and colours

Drug Monograph

Jun 2019
Table of Contents

Patient Info Sheet

May 2018

What it is used for

• For treating some types of kidney cancer, as well as gastrointestinal stromal tumors (GIST) - a rare cancer usually affecting the stomach or intestines, and a rare type of pancreas cancer.



You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration